Tirzepatide
Also listed as JD-2TR
Tirzepatide acts on GIP and GLP-1 receptors. It has been studied in human medicine products for blood sugar and metabolic effects.
Whole vial: 10 mg / 20 mg / 40 mg / 60 mg Vial math ↓
Why people look it up
Tirzepatide is well known because prescription versions are used for type 2 diabetes, chronic weight management, and certain sleep-apnea patients. JD-2TR is a seller code associated with tirzepatide in listed batch reports.
Type 2 diabetes blood-sugar controlFDA-APPROVED USE
Mounjaro is an FDA-approved tirzepatide medicine for type 2 diabetes; this status does not transfer to JD-2TR. Read source ↗
Applies to the named prescription product, not this research vial.
Chronic weight managementFDA-APPROVED USE
Zepbound is an FDA-approved tirzepatide medicine for a defined weight-management population, not this research vial. Read source ↗
Applies to the named prescription product, not this research vial.
Obstructive sleep apnea in adults with obesityFDA-APPROVED USE
The Zepbound label includes this specific population and indication. Read source ↗
Applies to the named prescription product, not this research vial.
The labels show the evidence for each claim. Open a row for its source.
Dosage at a glance
Dosage source summary
- Starting amount
- 2.5 mg
- Other label strengths
- 5 / 7.5 / 10 / 12.5 mg
- Adult maximum
- 15 mg
- How often
- Once weekly in the adult label
- Time on / time off
- Label increases are at least four weeks apart; this is not an on/off cycle.
- Route
- Subcutaneous manufactured medicine.
Named prescription product only. The middle cell lists other strengths, not a typical middle dose or directions for a dry vial.
These source amounts do not establish a safe human dose for a research vial.
Sources & individual reports
Named prescription product only. The middle cell lists other strengths, not a typical middle dose or directions for a dry vial. Source check: 2026-10-18.
Source coverage: 1 reviewed public account. Not a community consensus.
Report 1 ↗First-person account
- Amount reported
- 2.5 mg each time from a stated 10 mg dry vial
- How often reported
- weekly
- Reported duration / cycle
- duration not stated
- Route (how it was taken)
- injection stated; route not stated
What the account says: Poster said they were using 2.5 mg weekly and asked how to prepare a 10 mg dry vial. Replies offering mixing instructions were not counted as personal use.
Product match & source details
Product match: Tirzepatide dry vial described; JD-2TR code, seller and batch were not verified.
r/Peptidesource firsthand tirzepatide post · Posted: 2024-09-09 · Reviewed: 2026-10-03.
How much agreement is there? A dry-vial tirzepatide account is documented, but the JD-2TR seller code and batch were not verified. The prescription label is a separate evidence source.
Public sources last reviewed: 2026-10-03. Product identity and reported results were not independently verified. Source method →
Evidence, sources & vial math
What the research actually showsHuman studies, evidence limits and mechanisms
What has actually been studied?
The strongest evidence belongs to manufactured prescription tirzepatide products studied in clinical trials. FDA approval applies to those products and specific indications, not automatically to a research-only JD-2TR vial.
Evidence limits: The prescription product evidence does not authenticate or establish handling of this research vial. An online code or COA does not confer medicine approval.
Product status: Research-vial listings are not FDA-approved medicines. Approved-use labels on this page refer only to the named finished prescription product.
Human research
SURMOUNT-1 tirzepatide obesity trial 2022
What was found: Mean body-weight change at week 72 was greater in each tirzepatide group than placebo.
Main limit: The tested medicine, escalation, population, and monitoring are specific to the trial and do not verify JD-2TR or establish directions for its dry vial.
Study setup and amounts
- Who
- Adults with obesity or overweight plus a weight-related complication, without diabetes
- Number of participants
- 2539
- Study design
- Randomized, double-blind, placebo-controlled phase 3 trial
- Route
- Subcutaneous study product
- Amount studied
- Assigned maintenance groups of 5, 10, or 15 mg; escalation occurred during the first 20 weeks
- Frequency
- Once weekly
- Duration
- 72 weeks
- Outcome measured
- Percentage change in body weight and proportion losing at least 5%
Study and prescription-product amounts describe those sources. They do not select an amount for an online research vial.
How researchers think it might work
Tirzepatide activates two hormone receptors involved in blood-sugar and appetite signaling: GIP and GLP-1.
Show scientific explanation
The manufactured medicine is a GIP- and GLP-1-receptor agonist. Product effects and risks come from trials of that specific formulation. Read supporting source ↗
Vial & syringe mathTurn the vial total and liquid volume into concentration and syringe units
Vial & syringe math
Change the vial total and final liquid volume to see what each U-100 syringe mark represents.
The starting 1 mL is a math example. Enter your final mixed volume to update the numbers.
100 U-100 syringe units = 1 mL. These results assume the labeled amount is evenly mixed through the final liquid volume.
See source amounts as syringe units
Prescription product label. The 2.5 mg start, 5 mg after four weeks, and later 2.5 mg increases after at least four weeks are for the manufactured prescription medicine. They do not establish how to prepare or use a dry JD-2TR vial. Read the Mounjaro prescribing information (2026) ↗
| Source row | Amount | Liquid volume | U-100 units | Full amounts in one vial* |
|---|---|---|---|---|
| Starting amount (weeks 1–4) | 2.5 mg | — | — | — |
| After four weeks | 5 mg | — | — | — |
| Later label amount | 7.5 mg | — | — | — |
| Later label amount | 10 mg | — | — | — |
| Later label amount | 12.5 mg | — | — | — |
| Adult maximum on label | 15 mg | — | — | — |
*Whole amounts by mass, before handling loss. Flags identify amounts above the vial total, volumes above the 100-unit scale, or measurements below one unit. Source amounts describe the named product or study; they do not choose an amount for a research vial.
About this listingResearch-use-only status, seller names and additional background
A research material is not intended for human use. Its name or lab report does not establish suitability for a person. What research use only means →
Why two names? JD-2TR is the seller code connected with Tirzepatide in the linked batch records. Check the exact batch; a seller code alone does not verify its contents.
Compiled by PeptideWhy · Scientific sources last checked 2026-10-03 · Editorial policy · Corrections